Etrasimod and Breastfeeding

Summary of use during lactation

No information is available on the use of etrasimod during breastfeeding. Etrasimod is 98% bound to plasma proteins and unlikely to reach the breastmilk in large amounts, but it has a slow clearance and long half-life and is potentially toxic to the breastfed infant. Some guidelines recommend avoiding etrasimod while breastfeeding because of the lack of information;[1] however, the manufacturer's labeling does not recommend against the use of etrasimod in breastfeeding. Until more data become available, etrasimod should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug levels in milk and infant serum

Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information was not found as of the revision date.

References

1. Mahadevan U, Seow CH, Barnes EL, et al. Global consensus statement on the management of pregnancy in inflammatory bowel disease. Clin Gastroenterol Hepatol 2025;23 (11S):S1–S60.40874901 PubMed